These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 7933344

  • 1. Lipoprotein(a) risk in women and efficacy of ascorbate.
    Bostom AG.
    JAMA; 1994 Oct 19; 272(15):1169. PubMed ID: 7933344
    [No Abstract] [Full Text] [Related]

  • 2. Lipoprotein(a): implications for clinical practice.
    Block RC, Pearson TA.
    Curr Atheroscler Rep; 2005 Sep 19; 7(5):327-9. PubMed ID: 16105473
    [No Abstract] [Full Text] [Related]

  • 3. Editorial Lp(a) - the underestimated cardiovascular risk factor.
    Mellwig KP.
    Clin Res Cardiol Suppl; 2017 Mar 19; 12(Suppl 1):1. PubMed ID: 28236286
    [No Abstract] [Full Text] [Related]

  • 4. Lipoprotein(a), the rediscovered risk factor, or how to get "back to the future".
    Sabouret P, Angoulvant D, Ray KK.
    Arch Cardiovasc Dis; 2020 Mar 19; 113(3):147-151. PubMed ID: 32205042
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Triglyceride-rich lipoproteins and HDL: what do recent trials tell us?
    Stock J.
    Atherosclerosis; 2013 Jun 19; 228(2):329-31. PubMed ID: 23623013
    [No Abstract] [Full Text] [Related]

  • 7. Should pharmacotherapy targeting lipoprotein(a) be further expanded for patients with diabetes?
    Sun Y, Hasegawa K, Drexel H.
    Eur Heart J Cardiovasc Pharmacother; 2024 Jul 16; 10(4):278. PubMed ID: 38697932
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Search and rescue for hypotheses surviving AIM-HIGH, the niacin therapy earthquake: still problematic after the primary publication.
    Brinton EA.
    J Clin Lipidol; 2012 Jul 16; 6(4):312-7. PubMed ID: 22836067
    [No Abstract] [Full Text] [Related]

  • 10. Therapy for lowering lipoprotein (a) levels.
    Angelin B.
    Curr Opin Lipidol; 1997 Dec 16; 8(6):337-41. PubMed ID: 9412773
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Lipoprotein(a) as a key target in combined therapeutic approaches for cardiovascular disease.
    Brandão JAM, Meireles-Brandão LR, Coelho R, Rocha-Gonçalves F.
    Rev Port Cardiol (Engl Ed); 2019 Jul 16; 38(7):485-493. PubMed ID: 31530423
    [Abstract] [Full Text] [Related]

  • 15. Lipoprotein(a) and Cardiovascular Diseases.
    Miksenas H, Januzzi JL, Natarajan P.
    JAMA; 2021 Jul 27; 326(4):352-353. PubMed ID: 34236417
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Triglycerides and cardiovascular risk.
    Jones A.
    Heart; 2013 Jan 27; 99(1):1-2. PubMed ID: 23161618
    [No Abstract] [Full Text] [Related]

  • 19. Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study.
    Leebmann J, Roeseler E, Julius U, Heigl F, Spitthoever R, Heutling D, Breitenberger P, Maerz W, Lehmacher W, Heibges A, Klingel R, Pro(a)LiFe Study Group*.
    Circulation; 2013 Dec 17; 128(24):2567-76. PubMed ID: 24056686
    [Abstract] [Full Text] [Related]

  • 20. Managing the dyslipidemia of metabolic syndrome: beyond statin therapy.
    Jialal I, Smith G.
    Metab Syndr Relat Disord; 2012 Jun 17; 10(3):159-60. PubMed ID: 22568574
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.